Bio-Rad
Bio-Rad Laboratories Q2 Revenues Decline 6 Percent, Firm Lowers Full-Year Outlook
Bio-Rad is expecting a decline in revenues for the full year due to a slower pace of recovery among customers of its core businesses.
Bio-Rad Laboratories Maintains Full-Year Guide Despite Life Science Q1 Revenue Decline of 25 Percent
Premium
The firm expects sales in its clinical diagnostics business to offset declines in life sciences related in part to lower instrument sales.
360Dx Top 30 Falls 6 Percent in April
Of the 30 companies in the index, six companies saw their share price rise last month, while 24 companies saw their stock prices decline.
Oncocyte, Bio-Rad Partner to Globally Launch Transplant Test
The test is expected to launch in Q2 2024 to select academic transplant centers in the US and EU and more broadly in the second half of the year.
Bio-Rad, Allegheny Health Network Partner for ddPCR-Based Cancer Monitoring
The collaboration will use Bio-Rad's Droplet Digital PCR technology to gather clinical data for solid tumor MRD monitoring using AHN's patient samples.
Sep 25, 2023
Feb 17, 2023
Bio-Rad Q4 Revenues Flat, Miss Analyst Estimates
Oct 28, 2022
Jul 29, 2022